Valuation: InMed Pharmaceuticals Inc

Market Cap 6.92M 4.87M 4.28M 3.94M 3.67M 463M 7.06M 47.36M 18.35M 227M 18.29M 17.9M 791M P/E 2024
-0.26x
P/E 2025 -0.39x
Enterprise Value -3.46M -2.43M -2.14M -1.97M -1.83M -231M -3.53M -23.67M -9.17M -114M -9.14M -8.94M -395M EV / Sales 2024
-714,273x
EV / Sales 2025 -1,305,911x
Free-Float
99.88%
Yield 2024 *
-
Yield 2025 -

Last Transcript: InMed Pharmaceuticals Inc

Manager TitleAgeSince
Chief Executive Officer 63 15/06/2016
Director of Finance/CFO 53 19/02/2024
Chief Operating Officer 57 14/07/2022
Director TitleAgeSince
Director/Board Member 63 15/06/2016
Chairman 63 -
Director/Board Member 51 07/08/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6.92M
-2.19%+6.01%+66.90%+127.13% 57.65B
+0.55%+17.77%+80.01%+100.93% 55.14B
-0.31%+3.23%-13.38%-13.63% 23.53B
+0.17%+3.60%+9.80%+416.55% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+0.28%+5.51%+36.93%-30.58% 16.84B
-1.49%+1.65%+23.20%+180.92% 13.68B
+0.14%+9.60%+33.31% - 12.97B
-1.96%+4.12%+76.82%+135.08% 12.38B
Average -0.69%+5.56%+38.72%+113.57% 25.94B
Weighted average by Cap. -0.74%+4.62%+47.70%+116.52%

Financials

2024 2025
Net sales 4.6 3.24 2.84 2.62 2.44 307.78 4.69 31.47 12.19 151.07 12.16 11.89 525.78 4.94 3.48 3.06 2.81 2.62 330.87 5.04 33.83 13.11 162.41 13.07 12.78 565.22
Net income -7.68M -5.4M -4.75M -4.37M -4.07M -514M -7.83M -52.53M -20.35M -252M -20.29M -19.85M -878M -8.16M -5.75M -5.05M -4.64M -4.33M -546M -8.33M -55.86M -21.64M -268M -21.58M -21.11M -933M
Net Debt -5.65M -3.98M -3.49M -3.22M -3M -378M -5.77M -38.68M -14.99M -186M -14.94M -14.62M -646M -10.38M -7.31M -6.42M -5.91M -5.5M -695M -10.59M -71.03M -27.52M -341M -27.44M -26.84M -1.19B
Logo InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Employees
-